News|Articles|February 4, 2026

6 Psychiatry Headlines You Missed in January 2026

FDA approvals, priority review decisions, and new data on treatment response and mechanisms highlight a month of progress in MDD and ADHD.

January 2026 delivered a wave of consequential developments across psychiatry, spanning regulatory milestones, predictive treatment insights, and emerging biological and therapeutic frameworks for depression and ADHD. From the US Food & Drug Administration (FDA) approval of the first at-home neuromodulation device for treatment-resistant major depressive disorder (MDD) to a priority review for a potential first-in-class ADHD therapy, the month underscored continued momentum toward more personalized, accessible psychiatric care.